Open‐label use of systemic corticosteroids · preterm infants
It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
1 finding from 1 review
Combined outcome of mortality or BPD at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Mortality at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · people with bronchiectasis
1 finding from 1 review
Number of participants improved · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in number of participants improved compared with placebo (low certainty).
1 finding from 1 review
Lung function (spirometry indices) ‐ FVC (in L, end study minus baseline values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ diffusion capacity % predicted (end of study) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ RV % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ TLC % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Exacerbations · people with bronchiectasis
1 finding from 1 review
Pseudomonas aeruginosa (P aeruginosa) colonisation · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in pseudomonas aeruginosa (P aeruginosa) colonisation compared with placebo (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · people with bronchiectasis
1 finding from 1 review
FVC (% predicted) Change from baseline · people with bronchiectasis
1 finding from 1 review
Primary outcome · adults with subacute and chronic cough
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who achieved clinical cure or significant improvement (> 70% reduction in cough severity measure) at · adults with subacute and chronic cough
1 finding from 1 review
Secondary outcomes · adults with subacute and chronic cough
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who achieved clinical cure or > 50% reduction in cough severity measure at · adults with subacute and chronic cough
1 finding from 1 review
Clinical cure · adults with subacute and chronic cough
1 finding from 1 review
Severity of cough (mean improvement score) · adults with subacute and chronic cough
Inhaled corticosteroids (ICS) showed no clear difference in mean change in cough score Symptomatic cough severity measure as… compared with placebo (low certainty).
1 finding from 1 review